EYEGENE Inc.

Corporate Overview

• EyeGene took its first step in the development of innovative biopharmaceutical drugs when it was first established in June 2000. Since then, EyeGene has continued to research and develop innovative drugs to overcome the deterioration of the quality of life due to aging.
• EyeGene has two core technologies. EGT022 is a molecule for the treatment of ischemic diseases based on proteomic research. It is being developed as a treatment for diabetic retinopathy, pressure ulcers, wound healing, and Myocardial Ischemia /Reperfusion Injury. Various premium vaccines for adults are also being developed using EyeGene 's proprietary Adjuvant, which has been established through continuous research in the field of immunology.
• Ultimately, we have set a business goal to become a leader in the 21st Century Biotechnology field through the improvement in the quality of life by establishing various new treatments, preventative vaccines and diagnostic systems for the treatment and prevention of age-related diseases.

Core Value

• 

  Research in age-related diseases

  EyeGene, Inc. ‘s Corporate Identity (CI) stems from a composition of “EYE” and “Genome”. As these words convey, EyeGene, since its establishment, has focused on discovering the secrets behind ocular diseases and developing therapeutics based on our expertise in Proteomics and Immunology. Further, we are continuously striving in Research & Development of innovative new biological drugs for the treatment of aging-related degenerative diseases through technology obtained from research in the field of genomic and proteomic informatics.

• 

  Wide NETWORK

  EyeGene has established a network through strong alliances with University Hospitals. Further networks have been established with Yonsei University’s proteomics research laboratory, Yonsei University Medical Center’s Cardiovascular Product Evaluation Center, Sejong University’s department of pharmacology, and Korea Advanced Institute of Science and Technology. R&D is continuously progressing after the collaboration and license agreement with Huons for EG-Decorin (therapeutic for pressure ulcers), and EyeGene has established a wide network of working relationships not only on the domestic front with biotech companies such as N cbit and GeneMatrix, but also on globally with research institutes and CROs such as Ora, Optimed, Harlan and Comparative biosciences.

EyeGene Logo

EyeGene, Inc. ‘s Corporate Identity (CI) stems from a composition of “EYE” and “Genome”.